Market Overview

Pfizer Presents Phase 2 Data Which Shows Investigational Therapy PD-0332991 Plus Letrozole Improved Progression Free Survival vs Letrozole Alone

Related PFE
Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
Markets Little Changed Ahead Of 4th Of July Break
In Pursuit of Shire, AbbVie Eyes Lower Taxes in UK (Fox Business)

Pfizer Inc. (NYSE: PFE) today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer. For patients treated with the combination of PD-991 plus letrozole, median PFS was 26.1 months, a statistically significant improvement compared to the median PFS in women who received letrozole alone, which was 7.5 months (HR=0.37 [95% CI: 0.21, 0.63]; P <0.001). These data were presented today and featured in a press conference at the 35^th Annual San Antonio Breast Cancer Symposium (Abstract #S1-6).

Breast cancer is the most commonly diagnosed cancer^1 and the leading cause of cancer death among women worldwide.^2 Estrogen receptor positive, HER2- breast cancer represents approximately 60 percent of all cases of breast cancer.^3 Despite currently available treatments, survival rates for advanced or metastatic breast cancer remain low.^4

Posted-In: News

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free